Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has issued an announcement.
TOT BIOPHARM International Co. Ltd. announced changes to its board of directors and committee roles, effective from March 21, 2025. These updates include the appointment of Dr. Liu, Jun as the Executive Director and CEO, and adjustments in committee memberships, which are expected to enhance the company’s governance and strategic direction.
More about TOT BIOPHARM International Co. Ltd.
TOT BIOPHARM International Co. Ltd. is a Hong Kong-incorporated company operating in the biopharmaceutical industry. The company focuses on the development, manufacturing, and commercialization of oncology drugs, aiming to provide innovative therapies for cancer treatment.
YTD Price Performance: 13.41%
Average Trading Volume: 152,560
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$1.61B
For detailed information about 1875 stock, go to TipRanks’ Stock Analysis page.